TRUADVICE’s GSK GSK Stock Holding History

TRUADVICE’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$516K	Buy	15,000 +812	+6%	+$28.8K	0.2%	126
2023 Q2	$498K	Buy	14,188 +1,349	+11%	+$48.4K	0.18%	131
2023 Q1	$463K	Buy	+12,839	New	+$449K	0.18%	125

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRUADVICE's GSK Position: Q3 2023 in Review

TRUADVICE increased its GSK (GSK) stake by 5.7% in Q3 2023, buying an estimated $28.8K and bringing the position to 15,000 shares worth $516K. The position accounts for 0.2% of the portfolio, ranked #126.

TRUADVICE first reported a position in GSK in Q1 2023 and has held it in 3 quarters since. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

TRUADVICE held 15,000 shares of GSK worth $516K as of Q3 2023.
TRUADVICE bought 812 GSK shares in Q3 2023, an estimated $28.8K.
GSK made up 0.2% of TRUADVICE's portfolio in Q3 2023, its #126 holding.
TRUADVICE first reported a position in GSK in Q1 2023 and has held it in 3 quarters since.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on TRUADVICE's 13F filing for Q3 2023, filed 13 Nov 2023.